Toripalimab plus cryoablation for lung cancer with limited progression
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of an immunotherapy drug (toripalimab) and a freezing treatment (cryoablation) for people with advanced non-small cell lung cancer that has started to grow again in only a few spots after initial treatment. It aims to see if this approach can help control the cancer without switching to a completely new therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be a type called non-small cell lung cancer that has spread to other parts of the body (stage IV).
- Your cancer must not have certain gene mutations (called driver genes) and must have started growing again in only 1 to 5 spots, in no more than 3 organs, after your first treatment.
- You must be between 18 and 75 years old and in generally good health (able to do daily activities with little help).
- You must be willing to provide blood and tumor tissue samples for testing.
- You cannot have had certain prior treatments like targeted therapy or have active brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (sintilimab), chemotherapy, and a freezing treatment called cryoablation for people with advanced non-squamous non-small cell lung cancer that has not been treated before. The goal is to see if this combination is safe and effective.
This trial tests whether adding an immunotherapy drug (serplulimab) to a procedure called cryoablation (freezing tumors) works better than cryoablation alone for people with early-stage non-small cell lung cancer that has not spread. It is for patients who cannot or choose not to have surgery or radiation.
This trial uses a freezing technique (cryoablation) through a bronchoscope to shrink tumors blocking the main airways. It is combined with standard chemotherapy and immunotherapy (pembrolizumab) to treat advanced lung cancer that hasn't been treated before.
This trial tests whether combining pembrolizumab (an immune treatment) with a lung ablation procedure can be safer and more effective for advanced non-small cell lung cancer after standard first treatment fails or the cancer comes back. It may help shrink tumors and improve control of the disease.
This trial tests whether a combination of toripalimab (an immunotherapy drug) and chemotherapy can help prevent small cell lung cancer from coming back after surgery. It is for people who had an unexpected finding of small cell lung cancer after their tumor was removed.
This trial studies whether adding toripalimab (an immunotherapy medicine) to radiation can improve outcomes for people with operable stage II to IIIA non-small cell lung cancer. It’s designed for cancers that can be fully removed with surgery, and it aims to see if this combination helps more than radiation alone/standard care.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.